Showing results (11-20 of 41) with videos related to
Sort By:
Pageof 5
Breast Cancer Research and Treatment|March 19, 2020
Neoadjuvant treatment strategies for HER2-positive breast cancer: cost-effectiveness and quality of life outcomesM J Hassett, H Li, H J Burstein, et al.Journal of Immunology (Baltimore, Md. : 1950)|November 1, 1991
Humoral immune functions in IL-4 transgenic miceH J Burstein, R I Tepper, P Leder, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 1, 2011
CMF revisited in the 21st centuryE Munzone, G Curigliano, H J Burstein, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 10, 2005
Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapyH J Burstein, G Lieberman, D J Slamon, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 20, 2008
A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancerH J Burstein, A M Storniolo, S Franco, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 17, 2011
Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancerY Wu, M M Amonkar, B H Sherrill, et al.Breast Cancer Research and Treatment|March 19, 2009
Tolerability of and adherence to combination oral therapy with gefitinib and capecitabine in metastatic breast cancerE L Mayer, A H Partridge, L N Harris, et al.European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|November 10, 2016
Breast conservation following neoadjuvant therapy for breast cancer in the modern era: Are we losing the opportunity?C Criscitiello, G Curigliano, H J Burstein, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 3, 2011
Responses to subsequent anti-HER2 therapy after treatment with trastuzumab-DM1 in women with HER2-positive metastatic breast cancerE M Olson, N U Lin, P J DiPiro, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 9, 2021
Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021H J Burstein, G Curigliano, B Thürlimann, et al.Pageof 5